Lilly’s Gastric Cancer Drug Wins Approval From U.S. FDA

Eli Lilly & Co.’s gastric cancer treatment, a drug that analysts project may generate more than $1 billion in sales, gained approval from U.S. regulators.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.